Fact-checked by Grok 2 weeks ago

National Marrow Donor Program

The National Marrow Donor Program (NMDP) is a global nonprofit organization founded in 1987 that maintains the world's largest registry of potential unrelated donors for hematopoietic stem cell transplants, providing life-saving cell therapies to patients with blood cancers and disorders such as leukemia and sickle cell disease. With access to more than 42 million potential donors worldwide (as of 2024), including over 9 million in the United States and 270,000 cord blood units in the US registry (with access to nearly 811,000 cord blood units globally), NMDP facilitates matches between patients and donors to enable transplants that can cure or treat these conditions. Since its inception, NMDP has supported over 140,000 transplants (as of 2024), impacting thousands of lives annually through donor recruitment, transplant coordination, and patient financial assistance programs that provided $6.6 million in support in 2024 alone. NMDP's origins trace back to advocacy efforts in the late 1970s, inspired by families like that of 10-year-old Laura Graves, who received one of the first unrelated donor transplants in 1979, prompting her father and supporters to push for a national registry with congressional and medical backing. The program officially launched its first transplant in December 1987, matching donor Diane Walters with 6-year-old Brooke Ward, marking the beginning of a network that now includes hundreds of collection centers and transplant facilities across the U.S. and internationally. Initially focused on donation, NMDP expanded in 1994 to include peripheral blood stem cells and in 1998 to incorporate blood, broadening access to therapies for diverse populations. Beyond facilitation, NMDP drives innovation in by funding approximately 200 clinical trials and initiatives, including efforts to improve outcomes for underrepresented ethnic groups through diverse donor recruitment and haploidentical transplant studies. In partnership with the Center for International Blood and Marrow Transplant (CIBMTR), established in 2004, NMDP collects and analyzes data from transplants to advance treatments and address disparities in access. Rebranded from Be The Match in early to emphasize its broader role in cell and gene therapies, NMDP continues to evolve, forming NMDP BioTherapies in 2016 to support emerging technologies like CAR-T cell treatments. Its mission remains centered on creating a world where every patient receives timely, effective , supported by a strategic plan guided by an executive team and board of directors.

History and Background

Founding and Early Development

The origins of the National Marrow Donor Program (NMDP) trace back to 1979, when Robert and Joanne Graves, parents of 10-year-old Laura Graves, sought a transplant for their daughter after her diagnosis with . With no suitable family donor available, they pursued an unrelated donor match, leading to Laura receiving the first successful unrelated transplant for that year at Fred Hutchinson Cancer Research Center in . Laura died from a relapse of her in 1981, but her family's experience inspired continued advocacy for a national registry to facilitate matches between unrelated donors and patients, laying the groundwork for a coordinated effort to address the scarcity of donors for blood cancers and disorders. In 1986, the NMDP was formally established as a through a with the U.S. to create and manage the National Donor Registry, aimed at recruiting volunteer donors and matching them with patients in need of hematopoietic stem cell transplants. This initiative marked the beginning of a centralized system to support unrelated donor transplants, building on earlier and the growing of bone marrow transplantation as a viable treatment for life-threatening diseases. The registry quickly began recruiting donors, focusing initially on adults typed for key (HLA) markers to enable precise matching. A pivotal milestone occurred in December 1987, when the NMDP facilitated its first unrelated donor transplant: 49-year-old Diane Walters from donated to 6-year-old Brooke Ward from , who was battling . This procedure, performed at Medical Center, demonstrated the feasibility of the registry's matching process and boosted momentum for donor recruitment. By the early , the registry had grown to over 1 million volunteer donors by October 1993, reflecting rapid expansion driven by public awareness campaigns and partnerships with medical centers. During this period, the NMDP also began broadening its focus to include blood as an alternative source, launching a dedicated cord blood transplant program in 1998 to enhance options for patients lacking adult donor matches.

Evolution and Rebranding

In the , the National Marrow Donor Program (NMDP) significantly expanded its operations to incorporate new sources of hematopoietic cells, addressing limitations in donor matching for patients needing transplants. In 1994, the organization facilitated its first transplant using peripheral blood s (PBSC), marking a shift from alone to include this less invasive collection method. By 1998, NMDP launched its umbilical cord blood transplant program, integrating cord blood units into the registry to broaden availability, particularly for patients without fully matched adult donors. These developments increased the pool of potential sources and improved transplant success rates. Building on this growth, NMDP invested in research collaborations during the late 1990s and early 2000s to advance transplant science. A key milestone was the 2004 establishment of the Center for International Blood and Marrow Transplant Research (CIBMTR) through a partnership with the , creating a comprehensive database for tracking outcomes and supporting evidence-based improvements in . This collaboration exemplified NMDP's commitment to integrating clinical facilitation with rigorous research to enhance patient care globally. In 2011, NMDP rebranded its donor registry as Be The Match to heighten public engagement and underscore the critical role of individual donors in saving lives. This change simplified messaging around matching patients with compatible donors, aiming to accelerate recruitment efforts and raise awareness of the need for diverse registry participants. The rebranding proved effective in expanding the donor pool and positioning the organization as a more accessible advocate for transplant patients. The organization underwent another rebranding in January 2024, reverting to NMDP to encapsulate its broadened mission in and therapies beyond traditional matching. This update reflects advancements in partial-match transplants and innovative therapies, signaling a strategic pivot toward global leadership in equitable access to emerging treatments. Concurrently, in August 2023, NMDP adopted a five-year strategic plan for fiscal years 2024–2028, with a core pillar dedicated to expanding access by dismantling barriers such as socioeconomic disparities and underrepresentation in the donor pool, targeting a doubling of equity in lives impacted to reach 10,000 patients annually.

Mission and Activities

Core Objectives

The National Marrow Donor Program (NMDP) operates as a with a primary mission to save lives through for patients battling blood cancers and disorders, such as , , and . This mission encompasses facilitating access to hematopoietic cell transplantation (HCT) and supporting innovative treatments that harness blood-forming stem cells to replace diseased ones in patients. By focusing on , NMDP addresses critical needs in treating life-threatening conditions where traditional therapies fall short, ensuring that patients receive timely and effective interventions. NMDP's vision is to create a world where every patient can receive their life-saving without barriers, emphasizing universal access regardless of geographic, socioeconomic, or biological challenges. Central to this vision is a commitment to , exemplified by the Donor for All initiative, which seeks to increase diverse donor representation and safely expand transplant options using partially matched donors for patients with uncommon (HLA) types, particularly those from underrepresented ethnic and racial groups. This effort aims to reduce disparities in match rates, where patients of color historically face longer wait times and lower success probabilities due to limited donor diversity in registries. In advancing the entire cell therapy ecosystem, NMDP plays a pivotal role from foundational and clinical trials to facilitating transplants and providing post-transplant , fostering and among researchers, healthcare providers, and patients. This comprehensive approach includes accelerating scientific breakthroughs, such as improving post-transplant survival rates and minimizing complications, while building partnerships to integrate cell and gene therapies into standard . By addressing the full spectrum of needs, NMDP not only supports immediate patient outcomes but also drives long-term progress in curative therapies for blood disorders.

Key Programs and Initiatives

The National Marrow Donor Program (NMDP) provides comprehensive patient assistance programs to alleviate financial and logistical barriers to hematopoietic cell transplantation. Through the Patient Financial Assistance Program, NMDP offers grants covering unexpected medical costs, non-medical expenses such as housing, travel for treatments, and support for (GVHD) management, as well as pre- and post-transplant needs and crisis interventions. These grants are equitably administered to ensure patients, regardless of background, can access life-saving care. Additionally, the Patient Support Center delivers one-on-one navigation services, group sessions, and connections to peer support networks to guide patients and families through the transplant process. NMDP advances research efforts primarily through its partnership with the Center for International Blood and Marrow Transplant Research (CIBMTR), a collaborative initiative with the that maintains a global database of over 700,000 transplant outcomes. CIBMTR conducts observational studies, interventional trials, and data analysis to improve survival rates, reduce complications, and enhance for patients with blood cancers, , and other disorders. Key initiatives include the Donor for All program, which sponsors clinical trials such as 15-MMUD, , OPTIMIZE, and ACCELERATE to expand access to partially matched donors, and grant programs like the Amy Strelzer Manasevit Research Program for early-career investigators and the Barbara Buchbinder Nurse Research Program for research. These efforts have produced over 1,900 publications and support more than 185 ongoing studies. NMDP conducts educational outreach to healthcare professionals and the public to promote awareness and best practices in . For professionals, the organization delivers clinical education programs that convene experts to share advances in transplant procedures and outcomes. Public initiatives include free, accessible resources such as brochures, videos, and online materials tailored for patients, families, and communities, alongside targeted campaigns like the High School Outreach Program to inspire future healthcare leaders and encourage donor registration. These programs aim to demystify transplantation and foster informed decision-making. NMDP facilitates clinical trials to accelerate innovative therapies, exemplified by the Jason Carter Clinical Trials Search and Support (CTSS) program, which provides personalized navigation in English and Spanish to help patients identify and enroll in suitable trials. A notable case is that of Amelia, a young patient of mixed Indian and African American heritage with a rare HLA type, who received a successful transplant using a 6/8 mismatched unrelated donor through an NMDP-sponsored trial under the Donor for All initiative, enabling her cure where a full match was unavailable. This trial demonstrated improved outcomes with enhanced post-transplant , broadening access for underrepresented patients.

Registry and Donor Operations

The Be The Match Registry

The Be The Match Registry, operated by the National Marrow Donor Program (NMDP), serves as the world's largest hematopoietic cell registry, listing approximately 9.4 million volunteer donors and 246,500 units (as of June 2025) to facilitate matches for patients needing transplants. Searches of the registry also provide access to over 42 million potential donors and more than 800,000 units worldwide through partnerships. This vast database enables comprehensive searches for unrelated donors, emphasizing the critical role of scale in increasing match probabilities, particularly for patients from underrepresented ethnic backgrounds where diverse donor representation enhances equity in access. To join the registry, individuals must meet specific eligibility criteria, including being between the ages of 18 and 35, residing in the United States, its territories, or freely associated states, and satisfying health guidelines that exclude conditions like certain autoimmune diseases, active cancers, or infectious diseases that could compromise donation safety. These requirements ensure that potential donors are healthy and capable of providing viable cells, with the age range selected to optimize quality and quantity for transplantation. Upon registration, prospective donors receive a cheek swab kit to collect a sample for (HLA) typing, a process that analyzes genetic markers on to create a unique tissue profile essential for compatibility assessment. The sample is processed in a , and the resulting HLA data—covering key loci such as , B, C, DRB1, and others—is stored securely in the registry's database, allowing for rapid preliminary matching during patient searches. Registry maintenance involves ongoing responsibilities for enrolled donors to ensure the database remains accurate and effective, including updating contact information such as and phone number to enable prompt notification if selected as a potential match. Donors are also required to report any significant health changes that might affect their eligibility, such as new medical conditions, to protect both themselves and recipients, with the commitment typically lasting until age 61 unless voluntarily withdrawn.

Donor Recruitment and Matching Process

The donor matching process for the National Marrow Donor Program (NMDP) is initiated by a patient's transplant upon confirming the need for an unrelated donor. The submits the patient's high-resolution (HLA) typing, typically at loci A, B, C, and DRB1, to the NMDP for a preliminary search of the Be The Match Registry. This search identifies potential donors based on HLA compatibility, with an optimal match defined as 8/8 (full match at these four loci) or 10/10 (including additional loci such as DQB1), as these levels are associated with the lowest risks of graft failure and complications. For common HLA types, multiple potential matches may be identified quickly, while rare types require extended evaluation. Upon identifying preliminary matches, NMDP coordinates confirmatory testing to verify and donor suitability. This includes high-resolution HLA re-typing of both and donor, additional draws for infectious disease screening and cell counts, and a comprehensive to assess the donor's overall and ensure the donation is safe. Only donors passing these evaluations advance, with NMDP providing support throughout to maintain privacy and facilitate coordination between the donor and transplant center. If a suitable is confirmed, the donor receives detailed notification from NMDP about the opportunity , including information on the donation method and potential risks. The donor then provides , which is required before proceeding to collection. For patients from diverse ethnic backgrounds, where 8/8 probabilities can be as low as 29-46%, expanded searches incorporating 7/8 or 5/8 partial matches via the Donor for All initiative raise the likelihood of identifying a viable option to over 97%. To broaden access, NMDP maintains cooperative agreements with 48 international registries through the , enabling searches of more than 42 million global donors during U.S. patient queries. These partnerships, which facilitate about half of NMDP-mediated transplants involving international elements, ensure equitable access by tapping into diverse donor pools worldwide without requiring separate searches. The extensive scale of the , with millions of typed volunteers, underpins the efficiency of this matching system.

Cell Collection and Transplantation

Methods of Hematopoietic Cell Collection

Hematopoietic cells for transplantation are primarily collected through three methods facilitated by the National Marrow Donor Program (NMDP): peripheral blood stem cell (PBSC) collection, harvest, and blood collection. PBSC donation is the most common approach, accounting for approximately 90% of adult donations, as it is less invasive and allows for quicker recovery compared to surgical options. harvest is used in about 10% of cases, often preferred for pediatric recipients due to higher survival rates associated with this graft source. collection provides an alternative from newborn sources, offering readily available units without direct donor involvement. In PBSC collection, donors receive subcutaneous injections of , a , for 4-5 days to mobilize hematopoietic stem cells from the into the bloodstream. This is followed by , a non-surgical procedure lasting 4-6 hours, during which blood is drawn from one arm, passed through a machine that separates and collects the stem cells, and returned via the other arm. The process may require one or two sessions to obtain the necessary cell dose, and collected cells are then processed and shipped to the transplant center. Bone marrow harvest involves a surgical procedure performed under general anesthesia in a hospital operating room, typically lasting 1-2 hours. Physicians use multiple needle insertions into the posterior iliac crests of the pelvic bones to aspirate liquid containing stem cells, aiming to collect 1-2 liters of , which represents about 1-5% of the donor's total volume. The is filtered to remove bone fragments and blood clots before infusion into the recipient. This method is particularly suitable for younger patients or when a higher concentration of nucleated cells is needed. Umbilical cord blood is collected noninvasively after , once the baby is born and the is clamped and cut. Trained medical staff drain the remaining blood from the and into a sterile , a process that takes 5-10 minutes and poses no risk to the or . The collected volume, typically 40-150 mL, is transported to an NMDP-accredited for processing, which includes volume reduction to concentrate cells and infectious testing. Qualified units are then cryopreserved by slow freezing in (DMSO) and stored in at -196°C for potential future use. Donors undergoing PBSC or bone marrow collection commonly experience temporary side effects, which are managed with over-the-counter medications and supportive care. For PBSC donors, often causes bone pain, muscle aches, headache, and fatigue, affecting most donors but resolving within days after injections cease; may lead to mild tingling, , or cramps due to the , which typically subside immediately post-procedure. Bone marrow donors may report back or hip soreness, fatigue, and bruising at sites for several days to weeks. Recovery timelines vary, with PBSC donors generally returning to normal activities in about 1 week and bone marrow donors in 2-3 weeks, though full marrow regeneration occurs within 4-6 weeks. Serious adverse events are rare, occurring in less than 1% of cases for both methods. Cord blood donation involves no side effects for the family, as it utilizes medical waste from birth.

Transplant Facilitation and Support

The National Marrow Donor Program (NMDP) coordinates the logistics of transporting hematopoietic cells to transplant centers to ensure timely delivery for patient treatment. Peripheral blood stem cells (PBSC) and products are shipped fresh via dedicated couriers, typically reaching the transplant center within 24 hours for domestic shipments and up to 72 hours for international ones, while units are cryopreserved and transported in dry shippers for stability during global shipment. NMDP employs trained couriers who handle these products under strict temperature-controlled conditions, with arrangements designed to reduce delays and maintain cell viability. Following transplantation, NMDP supports long-term outcome monitoring through its partnership with the Center for International Blood and Marrow Transplant Research (CIBMTR), which collects comprehensive data on recipients of NMDP-facilitated transplants. This includes detailed reporting on graft function, complications, survival rates, and via standardized forms submitted by transplant centers, enabling evidence-based improvements in care protocols. CIBMTR's database tracks over 700,000 patients, with nearly all U.S. allogeneic transplants represented, to analyze long-term effects and inform clinical guidelines. To address barriers for underserved patients, NMDP provides financial assistance programs that cover expenses to transplant centers, copays, and other non-medical costs such as housing and nutrition, particularly for those facing socioeconomic challenges. These grants, administered through the Patient Support Center, help ensure equitable access to care before and after transplant, with eligibility assessed by transplant teams or NMDP navigators. In 2024, such programs distributed over $6.6 million to support patients navigating these hurdles. NMDP integrates transplant facilitation with clinical trials for experimental cell therapies, partnering with institutions to incorporate innovative approaches like post-transplant for prevention and CAR T-cell therapies combined with allogeneic transplants. Through NMDP BioTherapies, the supports manufacturing and delivery of advanced products for trials targeting blood cancers, such as TCR-based therapies for . This coordination allows seamless progression from standard matching to experimental interventions, enhancing outcomes for high-risk patients.

Rationale and Impact

Need for Large-Scale Registries

The (HLA) system exhibits extensive genetic diversity, with thousands of alleles across key loci such as , -B, -C, -DRB1, and -DQB1, making precise matching essential for successful to minimize risks like . Only about 30% of patients requiring such transplants have an HLA-identical sibling donor available within the family, leaving the majority dependent on unrelated donors from large registries to achieve compatible matches. This HLA variability necessitates expansive donor pools to identify suitable unrelated matches, as smaller or less diverse registries often fail to represent the full spectrum of patient HLA types. Ethnic and racial disparities exacerbate these challenges, as underrepresented groups in donor registries face significantly lower match rates due to differences in HLA frequencies inherited across populations. For instance, Black/African American patients have approximately a 29% chance of finding an HLA-matched unrelated donor, compared to 47% for Asian/ patients and higher rates for patients, stemming from underrepresentation—such as Black donors comprising only about 7% of major U.S. registries despite greater HLA in these ancestries. These inequities highlight the critical need for large-scale, demographically diverse registries to improve equity in transplant access. Mathematical models of donor matching demonstrate that expanding registry size substantially boosts the probability of identifying a compatible donor, following a sigmoidal curve where gains accelerate in intermediate ranges before plateauing, effectively yielding exponential-like improvements for underrepresented HLA types as pools reach millions. For example, simulations indicate that a registry of 1 million donors can achieve around 64% match likelihood for certain four-locus HLA profiles, with further growth to larger scales enhancing outcomes particularly for diverse patients. Registries like the NMDP's Be The Match address these needs through their extensive donor pools. Umbilical cord blood units further expand transplant options by tolerating greater HLA mismatches—often up to one or two loci—compared to donors, enabling viable transplants for patients lacking perfect matches in adult registries. This permissiveness arises from the immature immune cells in , reducing severe risks despite imperfect HLA compatibility, thus broadening access for urgent cases.

Achievements and Statistical Outcomes

Since its inception in 1987, the National Marrow Donor Program (NMDP) has facilitated more than 140,000 transplants worldwide, marking a significant milestone in advancing for patients with life-threatening blood cancers and disorders. By 2021, NMDP had achieved its 100,000th donor-recipient match, reflecting steady growth in its capacity to connect patients with compatible donors. Annual transplant volumes have surpassed 6,000 in recent years, with 7,994 lives impacted through in 2024 alone, demonstrating the program's expanding scale and efficiency. Improvements in survival rates for unrelated donor transplants represent a core achievement, driven by advancements in donor matching and post-transplant care. Over the past five years, the one-year for these transplants has risen from 42% to 60%, aligning closely with outcomes from related donor procedures. For patients with high-risk receiving unrelated donor hematopoietic cell transplants early in their disease course, one-year survival now reaches 60-70%, underscoring the impact of refined HLA matching protocols. Long-term success has also advanced, with three-year survival improvements of 7-10% attributed to better donor selection and supportive therapies. NMDP's targeted recruitment efforts have enhanced within its registry, leading to substantial gains in rates for underrepresented ethnic groups. These initiatives have boosted probabilities for groups like and Hispanics, where earlier rates were as low as 27-47%, contributing to more equitable access to transplants. Through its partnership with the Center for International and Transplant Research (CIBMTR), NMDP has contributed data from over 700,000 patients to establish global standards in hematopoietic cell transplantation. This vast dataset, including outcomes from NMDP-facilitated procedures, supports more than 1,900 publications and 185 ongoing studies, informing evidence-based guidelines and clinical trials worldwide.

Partnerships and Organization

International Collaborations

The National Marrow Donor Program (NMDP) engages in extensive international collaborations to enhance access to unrelated donors and units for patients worldwide, primarily through its membership in the World Marrow Donor Association (WMDA). These cooperative agreements connect NMDP with registries and organizations in 45 countries outside the , facilitating the exchange of hematopoietic stem cells across borders. As a member of WMDA, established in , NMDP contributes to and benefits from a global network that promotes standardized practices for donor recruitment, matching, and product transport, ensuring ethical and efficient international transplants. A key aspect of these partnerships is the real-time access to approximately 34 million potential donors, contributing to a worldwide pool of over 43 million, enabling physicians to search a combined pool that improves match rates for diverse patient populations. This expanded search capability, integrated into NMDP's matching process, supports 48 transplant centers and includes units from global banks, with approximately 761,000 units available through WMDA-affiliated inventories as of 2025. exchanges with European registries, such as those coordinated via WMDA's Cord Blood Working Group, allow for the shipment of units to U.S. patients and vice versa, addressing shortages in rare HLA types and reducing wait times for transplantation. NMDP also advances joint research and training programs internationally, leveraging collaborations like the Center for International Blood and Marrow Transplant Research (CIBMTR), which NMDP co-sponsors with the Medical College of Wisconsin. CIBMTR collects and analyzes transplant outcome data from over 310 global centers, fostering knowledge sharing on best practices for cell collection, infusion, and post-transplant care. Training initiatives include workshops and certification programs aligned with WMDA standards, equipping international partners with tools for donor eligibility assessment and product quality assurance. Specific initiatives emphasize global transplant data sharing for rare diseases, where CIBMTR's database—encompassing outcomes from thousands of procedures—enables collaborative studies on survival rates and complications in conditions like severe aplastic anemia and inherited metabolic disorders, ultimately informing personalized treatment strategies worldwide.

Domestic Registries and Networks

The National Marrow Donor Program (NMDP) maintains extensive partnerships with U.S. donor centers to facilitate the , collection, and of hematopoietic cells for transplantation. These collaborations ensure that potential donors across all 50 states, , and can be efficiently identified, evaluated, and mobilized when matched with patients. NMDP works with a comprising numerous domestic donor centers, including both NMDP-operated facilities and contracted partners, to handle for peripheral blood stem cells and surgical collection for at hospital-based sites. A key example of targeted is NMDP's partnership with the Gift of Life Marrow Registry, an associate donor registry that focuses on underrepresented populations, such as Jewish communities, to expand the diversity of the donor pool. This alliance enhances collection capacity and streamlines the donation experience, allowing Gift of Life donors to be integrated into NMDP searches and collections at shared facilities, like the Adelson Gift of Life-NMDP Collection Center in . Through such cooperative efforts, NMDP coordinates with organizations to boost registry membership and improve match rates for patients in need. NMDP's integration with federal programs further strengthens its domestic infrastructure. It operates under a contract with the (HRSA), part of the U.S. Department of Health and Human Services (HHS), to manage the C.W. Bill Young Cell Transplantation Program, which supports registry operations and transplant facilitation. Additionally, NMDP collaborates with the Department of Defense, including the Navy's Naval Medical Research Center in , to include military personnel in the donor registry and conduct collections at dedicated sites. Complementing these efforts, NMDP coordinates with more than 150 transplant centers across the to enable seamless patient referrals and post-transplant support. This allows transplant physicians to access NMDP's registry for matches, coordinate cell transport, and participate in clinical outcomes reporting through affiliated systems like the Center for International Blood and Marrow Transplant Research (CIBMTR). These domestic connections form the core of NMDP's operational efficiency in delivering unrelated donor transplants nationwide.

Governance and Sustainability

Organizational Structure and Leadership

The National Marrow Donor Program (NMDP) operates as a governed by a that provides strategic oversight and guidance to the executive team. The board ensures alignment with the organization's to advance and save lives, with Judith Gasson, PhD, serving as chair. An affiliated NMDP Foundation board focuses on stewardship of philanthropic funds to support these efforts. The executive team, comprising senior leaders with expertise in medicine, operations, finance, and strategy, drives day-to-day decision-making and long-term vision. Amy L. Ronneberg has led the organization since March 2020, overseeing its evolution including the rebranding to emphasize global leadership. Key roles include Steven Devine, MD, who directs clinical and research initiatives as executive lead of the Center for International Blood and Marrow Transplant Research (CIBMTR); Jim Graham, managing IT systems for donor matching and data security; Katherine Heyerdahl, , handling fiscal operations; and senior vice presidents such as Jamie Margolis, , for member, donor, and product operations; Julie Smolich for patient and provider services; and Erica Jensen for strategy and advancement, which encompasses global partnerships. This leadership structure fosters collaboration across functions to enhance transplant outcomes. NMDP's internal divisions are organized around core functions to support its mission. Registry operations, managed under donor and product services, handle , , and coordination of the world's largest hematopoietic cell donor registry. efforts, integrated through CIBMTR, focus on advancing scientific knowledge in blood cancers and disorders. Patient services provide direct support to individuals and healthcare providers, including and . Global partnerships fall under strategic advancement, facilitating collaborations for donor access and . These divisions enable efficient from donor to post-transplant care. Strategic planning at NMDP involves a rigorous, stakeholder-driven to set priorities and measure progress. The organization's current five-year strategic plan, approved by the board, was developed through extensive input including surveys, focus groups, advisory sessions, and over 20 brainstorming meetings with more than 1,000 participants from the transplant community. This plan outlines pillars such as accelerating cell therapy progress, serving as a world-class partner, and expanding equitable access, with annual goals tied to key metrics in areas like lives impacted, excellence, , employee thrive, and sustainability. Departments align their objectives annually to these visions, ensuring adaptive decision-making amid evolving medical needs. The organization employs approximately 1,800 dedicated staff members, with nearly 1,000 based in and more than 800 worldwide, with roles emphasizing advocacy to increase donor diversity, IT innovations for rapid matching algorithms, and clinical support for transplant coordination and patient outcomes. This workforce, headquartered in with global reach, collaborates to operationalize NMDP's goals.

Funding Sources and Financial Overview

The National Marrow Donor Program (NMDP) sustains its operations through a diversified portfolio of streams, with the majority derived from search and fees associated with facilitating hematopoietic cell transplants and banking services. In 2024, these fees generated $560.35 million, representing approximately 87% of , and encompass charges for donor matching, product acquisition, and inventory management through programs like the National Inventory. Federal contracts and cooperative agreements provide a significant portion of dedicated funding, primarily from the (HRSA) under the C.W. Bill Young Cell Transplantation Program, totaling $50.34 million in 2024, including $23.17 million from HRSA for registry maintenance and inventory support. Additional federal sources include contracts with the Department of the Navy ($13.75 million) and the ($1.65 million) for research and procurement activities. Philanthropic contributions, channeled through the Be The Match Foundation, added $35.49 million in unrestricted and restricted donations, supporting patient financial assistance programs that aided 3,300 families with $6.6 million in 2024. Campaigns such as NMDP Unite and regional galas raised over $1.1 million in and $565,000 in , while partnerships like HOSA contributed more than $200,000 since 2020 for donor recruitment. Research grants are integrated into federal contracts and philanthropic contributions, funding initiatives in transplant outcomes and registry expansion without separate itemization exceeding $1.65 million from NIH. NMDP's overall financial scale reflects its nonprofit mission, with total revenue of $646.38 million and expenses of $638.84 million in , resulting in a $36.75 million increase in net assets. Budget allocations prioritize medical services (60%), (17%), and donor recruitment (7%), ensuring support for the organization's extensive registry and transplant facilitation efforts. Financial is maintained through annual audited reports prepared under Generally Accepted Accounting Principles () by Baker Tilly, with no material weaknesses identified, alongside public IRS filings and high ratings from (4/4 stars) and GuideStar Platinum Seal. These measures affirm compliance with nonprofit standards and accountability to stakeholders.

References

  1. [1]
    NMDP (Formerly Be The Match) Global Nonprofit in Cell Therapy ...
    NMDP (formerly Be The Match & National Marrow Donor Program) is a global leader in bone marrow & blood stem cell transplant, driving life-saving research.Careers at NMDPJoin the RegistryAbout UsMy NMDPGet Involved
  2. [2]
    Cooperative Registries - NMDP
    When a doctor searches the NMDP RegistrySM on behalf of a patient, they have access to 42 million potential donors around the world thanks to our partnerships ...Missing: size | Show results with:size
  3. [3]
    [PDF] At Work in South Carolina - NMDP
    Oct 31, 2025 · Since 1987, NMDP has facilitated more than 140,000 transplants. In 2024, NMDP impacted 7,994 lives through cell therapy. • Today, patients ...
  4. [4]
    The Evolution of Hematopoietic Stem Cell Transplantation to ... - NIH
    May 29, 2024 · The History of NMDP. NMDP exists today because the family of 10-year-old Laura Graves turned to alternative treatment options after she ...<|control11|><|separator|>
  5. [5]
    Our History - Network | NMDP
    NMDP started in 1979 after a bone marrow transplant inspired by a child's leukemia. The first transplant was in 1987, and it was initially called the National ...
  6. [6]
    About Us | NMDP (Formerly Be The Match)
    ### Summary of NMDP
  7. [7]
    The National Marrow Donor Program 20 Years of Unrelated Donor ...
    In 1988, 54 transplants were performed; in 1997, 879 transplants were performed; and in 2007, 2640 adult transplants were facilitated by the NMDP. PBSC was ...
  8. [8]
    Effect of HLA incompatibility in marrow transplantation from ...
    As of October 1993, the National Marrow Donor Program (NMDP) has accrued more than 1 million volunteers typed for HLA-A and B, including 200,000 typed for ...<|control11|><|separator|>
  9. [9]
    About CIBMTR
    CIBMTR (Center for International Blood & Marrow Transplant Research) is a research collaboration between the Medical College of Wisconsin (MCW) and NMDP.Missing: history | Show results with:history<|control11|><|separator|>
  10. [10]
    [PDF] Transplant - Minnesota Medical Association
    May 19, 2011 · In addi- tion to rebranding the registry as the Be the Match Registry ... The National Marrow Donor Program now operates independently. 14 ...
  11. [11]
    Be The Match® Affirms Global Leadership in Life-saving Cell
    Jan 8, 2024 · National Marrow Donor Program®/Be The Match® is proud to unveil its new organizational name and brand: NMDP. Find cures. Save lives. ...Missing: date | Show results with:date<|control11|><|separator|>
  12. [12]
    None
    **Summary of NMDP's Five-Year Strategic Plan (Fiscal Years 2024-2028)**
  13. [13]
    What We Do | NMDP (Formerly Be The Match)
    Our mission is simple: We save lives through cell therapy. Who we are. We're a global nonprofit leader in cell therapy, helping find cures and save lives for ...
  14. [14]
    Commitment to health equity | Advancing access to cell therapy
    Learn how NMDP advances health equity by expanding access to life-saving cell therapies and supporting diversity through strategic initiatives.​​Our Commitment To Equity In... · Rebuilding Trust In Health... · ​removing Barriers To...Missing: 2020s | Show results with:2020s
  15. [15]
    NMDP Donor for All: Ensuring every patient finds a match
    Our Donor for All initiative aims to safely unlock access to blood stem cell transplant through many innovative research efforts using partially matched donors.
  16. [16]
    About Us - Network | NMDP
    At NMDP, we save lives through cell therapy. Explore how we're expanding access to treatment so every patient can receive their life-saving cell therapy.Missing: five- 2020s
  17. [17]
    [PDF] Five-Year Strategic Plan - NMDP
    unrelated, volunteer donors. Six-year-old Brook Ward received a marrow donation from Diane Walters in our organization's very first transplant in 1987.Missing: Brooke | Show results with:Brooke
  18. [18]
    Patient Financial Assistance Program - Network | NMDP
    NMDP offers grants for unexpected barriers, medical costs, non-medical expenses, GVHD, travel, pre/post-transplant, and crisis grants. Patients must be ...
  19. [19]
    Patient Financial Assistance Program - NMDP serving Monaca, PA
    The NMDP's (formerly known as the National Marrow Donor Program and Be The Match) goal is to equitably administer financial assistance to help patients get ...
  20. [20]
    Patient Care & Family Support Information - NMDP
    Beyond being a source of information, we provide support. Whether you need financial assistance, one-on-one time with a patient navigator, group sessions or ...
  21. [21]
    Blood Cancer, Sickle Cell & Transplant Research - NMDP
    Transplant science is advanced through research. NMDP funds research to advance cell therapy for patients with blood cancers, sickle cell disease and other ...
  22. [22]
    About our research - Network | NMDP
    Through our Donor for All initiative, NMDP is sponsoring a series of clinical trials conducted by CIBMTR, known as 15-MMUD, ACCESS, OPTIMIZE and ACCELERATE. The ...
  23. [23]
    How We Help Patients | NMDP (Formerly Be The Match)
    Providing clinical education to health care professionals. We bring together experts in the field of cell therapy to deliver education on the latest advances ...
  24. [24]
    Educational materials to learn about transplant - NMDP
    Our free, easy-to-understand resources can help you make informed medical decisions and navigate your transplant journey.Missing: outreach | Show results with:outreach
  25. [25]
    NMDP - Facebook
    Jun 20, 2025 · You or anyone in your school might be able to save any patients around the world. We've launched a High School Outreach Program to educate ...
  26. [26]
    Helpful Bone Marrow Transplant Organizations - nbmtLINK
    Be The Match is operated by the National Marrow Donor Program, a nonprofit that matches patients with donors, educates health care professionals and conducts ...
  27. [27]
    NMDP Donor for All Research Gave Amelia a Chance for a Cure
    Aug 29, 2024 · Original published date: 8/29/2024. Amelia didn't have a full donor match. New research made a blood stem cell transplant possible.
  28. [28]
    BE THE MATCH: Presentation Recap - Rotary Club of Akron
    The Be the Match Registry is the world's largest hematopoietic cell registry, listing more than 22 million individuals and more than 300,000 cord blood units.
  29. [29]
    Join the Registry | NMDP (Formerly Be The Match)
    Join the registry to donate bone marrow, peripheral blood stem cells or cord blood & help save a life. NMDP maintains the most diverse registry in the world.Blood stem cell donation ​FAQs · Manage your donor profile · PBSC donationMissing: size | Show results with:size
  30. [30]
    Joining the Registry | Blood Stem Cell - HRSA
    Mar 11, 2025 · NMDPSM is focused on recruiting people ages 18 to 40 because medical research shows that younger donors are best for patients and provide the ...
  31. [31]
    How Bone Marrow & Blood Stem Cell Donors Are Matched - NMDP
    We use the cheek swab you supply when you join the NMDP RegistrySM to determine your HLA type. Matching donors and patients using HLAs. For HLA matching, ...How Matching Blood Stem Cell... · Matching Donors And Patients... · How Often Are Blood Stem...
  32. [32]
    What is HLA? HLA Basics, Typing & Matching​ Overview​ | NMDP​
    Human leukocyte antigen (HLA) are proteins found on most cells in the body. HLA are used by doctors to help match blood stem cell donors with patients.How Does Hla Typing And... · Hla Matching · Who Am I Most Likely To...
  33. [33]
    Manage Your Donor Profile & Update Contact Info - NMDP
    Manage your donor profile & update your contact information. NMPD (formerly Be The Match) needs to reach you when you're matched with a patient.
  34. [34]
    https://www.nmdp.org/patients/understanding-transplant/finding-a-donor/hla-typing-matching
  35. [35]
    What to Expect: PBSC Donation Timeline - NMDP
    You'll take a physical exam and give blood samples to make sure that donation is safe for you and the patient. You'll also find out which type of donation ...
  36. [36]
    [PDF] A Donor's Guide to Donation - NMDP
    These steps include participating in an information session, keeping appointments for additional blood tests and a physical exam—all before the donation ...
  37. [37]
    Bone Marrow Donation Overview & Process - NMDP
    Receive a physical exam and blood tests to ensure donation is safe for you. Throughout your journey, NMDP experts will guide and support you every step of ...
  38. [38]
    Peripheral Blood Stem Cell ​(PBSC) ​Donation Process Overview
    Undergo additional testing to ensure the best match. Attend an information session to answer any questions. Receive a physical exam and blood tests.NMDP Collection Centers · See the donation timeline · FAQs
  39. [39]
    NMDP Donor for All initiative
    NMDP's Donor for All initiative is establishing a new standard of care using mismatched donors to ensure all patients receive their life-saving cell ...
  40. [40]
    Global Transplant Center Network - NMDP
    Each donor or cord blood unit (CBU) search through NMDP provides patients with access to more than 42 million potential donors and more than 800,000 CBUs. These ...Transplant Centers · Donor Centers · Apheresis Centers And...Missing: agreements | Show results with:agreements
  41. [41]
    ​​Umbilical ​Cord Blood Donation Overview - NMDP
    Learn how donating your baby's umbilical cord blood can help save lives​ as NMDP walks you through the donation process and what to keep in mind.​​What Is Umbilical Cord Blood... · The Impact Of Umbilical Cord... · How To Donate Umbilical Cord...Missing: cryopreservation | Show results with:cryopreservation
  42. [42]
    Quadratus Lumborum Blocks for Pediatric Bone Marrow Harvesting
    Oct 25, 2023 · Bone marrow is the preferred graft source in pediatric patients, and it is used in more than two-thirds of cases [5,6]. Many of these are ...
  43. [43]
    Frequently Asked Questions (FAQ) - Blood Stem Cell - HRSA
    Less than 1 percent (0.6%) of donors experience serious side effects from filgrastims. The PBSC donation procedure can also have side effects. Some donors ...
  44. [44]
    Recovery of Unrelated Donors of Peripheral Blood Stem Cells ...
    Of the entire cohort, 262 donated PBSC and 264 donated BM; 372 (71%) donors were from domestic and 154 (29%) from international centers (145 German and 9 ...Missing: percentage | Show results with:percentage
  45. [45]
    RAPID TRANSPORT AND INFUSION OF HEMATOPOIETIC CELLS ...
    The NMDP ensures transportation arrangements for the courier minimizes transit time from collection to transplant centers. Ninety-three percent of BM grafts ...Missing: facilitation | Show results with:facilitation
  46. [46]
    NMDP Advanced Cell Therapy Lab Solutions
    Cryopreservation. Cryopreservation through NMDP aims to: Increase donor availability by giving donors, donor centers or registries, apheresis centers and ...
  47. [47]
    [PDF] FRAGILE MEDICAL MATERIALS - NMDP
    is a trained courier transporting human cells for transplantation from to for a patient who is awaiting a stem cell transplant.Missing: facilitation logistics
  48. [48]
    Our Impact - CIBMTR
    Now with data from more than 700,000 patients, more than 1,900 publications, and more than 185 ongoing studies and clinical trials, CIBMTR is at the forefront ...
  49. [49]
    Recipient & Donor Data - CIBMTR
    CIBMTR's Research Database contains cellular therapy information for recipients and their donors. CIBMTR collaborates with centers from around the world.
  50. [50]
    Financial assistance before and after transplant - NMDP
    An NMDP patient navigator or your transplant center team—usually a social worker—can help you determine if you may be eligible for a grant and apply on your ...Missing: underserved | Show results with:underserved
  51. [51]
    First Patient Treated in ACCELERATE Clinical Trial - Network | NMDP
    Aug 6, 2025 · Research led by NMDP and CIBMTR has demonstrated that MMUD hematopoietic cell transplant (HCT) using PTCy-based GVHD approaches result in ...
  52. [52]
    BlueSphere Bio To Partner with NMDP BioTherapies for the ...
    Jun 25, 2024 · BlueSphere Bio's BSB-1001 therapy could provide a novel and effective way to treat patients with AML, ALL, and MDS in combination with allogeneic stem cell ...
  53. [53]
    Emerging research could increase access to blood stem cell ...
    In addition, Auletta says that the NMDP/Be The Match is working to “transform the post-HCT landscape through the use of cell therapies.” Following HCT ...
  54. [54]
    Optimal HLA Matching in Haematopoietic Cell Transplantation - PMC
    Only 30% of patients in need of a hematopoietic cell transplant will have an HLA identical sibling to serve as the donor.
  55. [55]
    Bone marrow donor registries: the relation between ... - PubMed - NIH
    Nov 15, 1989 · The determinants of the probability of achieving a given quality of match with a given registry size are (1) the genetic heterogeneity within ...Missing: impact exponential
  56. [56]
    How ethnicity helps in matching - DKMS
    Black/African American patients : 29% chance – The lowest likelihood of finding a match, making it even more critical to increase donor participation.Missing: rates 20-30%
  57. [57]
    Expert Speaks to Disparities in Stem Cell Transplant for Blood ...
    Oct 17, 2023 · ... match in the stem cell donor registry compared with 29% of Black patients, 47% of Asian/Pacific Islander patients, and 48% of Hispanic/Latino ...
  58. [58]
    Racial disparities in hematopoietic cell transplantation in the United ...
    The probability of finding a match within the registry is estimated to be 0.93 for Whites, 0.82 for Hispanics, 0.77 for Asian Americans and 0.58 for Blacks. HCT ...
  59. [59]
    https://pubmed.ncbi.nlm.nih.gov/2804379/
  60. [60]
    Breakthroughs, Advancements & Milestones - NMDP
    NMDP's history is shaped by scientific breakthroughs and accomplishments, with the goal of creating a world where every patient can receive their life-saving ...
  61. [61]
    Leading research to save more lives
    ... million donors and registry members. As we celebrate World Marrow Donor Day ... NMDP℠ is entrusted and under contract to operate the federally ...<|control11|><|separator|>
  62. [62]
    Significant Improvement in Survival after Unrelated Donor ... - NIH
    The absolute survival improvement of 7-10% at three years is clinically meaningful. Deaths are relatively uncommon after three years, and a substantial number ...
  63. [63]
    East Meets West—Impact of Ethnicity on Donor Match Rates in the ...
    The 6/6 allele aggregate match rate rose from 52% to 62% for the entire registry cohort. The increase of donor–recipient matches by subethnicity ranged from 6.8 ...
  64. [64]
    A study of younger newly recruited potential donors - PubMed Central
    Jun 1, 2023 · Minority groups are more likely to drop out of the donor registry, and have lower rates of finding matched donors compared to White adults.
  65. [65]
    None
    ### Summary of International Collaborations and Related Facts
  66. [66]
    About WMDA
    Since 1994, WMDA has united experts from over 57 countries to ensure safe, ethical, and efficient donor matching. WMDA provides a global platform to streamline ...<|control11|><|separator|>
  67. [67]
    Cord blood transplant - Network | NMDP
    Access a listing of domestic and international cord blood banks, including identification codes; the median turnaround time of typing and shipment requests; and ...Missing: joint exchanges European
  68. [68]
    International exchange of cord blood units: the registry aspects
    This paper describes the aims and activities of the World Marrow Donor Association (WMDA) Cord Blood Working Group (CBWG) which was established in 2007 to ...Missing: joint research training European
  69. [69]
    Global Partnerships & Network for Cell Therapy - NMDP
    Together, we promote global collaboration and best practices for both donors and patients. This network of registries, cord blood banks, researchers and ...Nmdp Global Network · Cibmtr® (center For... · Blood And Marrow Transplant...Missing: agreements | Show results with:agreements
  70. [70]
    Collaborations - CIBMTR
    CIBMTR manages the BMT CTN Data and Coordinating Center with NMDP and The Emmes Company, a contract research organization. ... CIBMTR is a research collaboration ...Missing: history | Show results with:history
  71. [71]
    Center for International Blood and Marrow Transplant Research
    The CIBMTR facilitates critical, cutting-edge research that has led to increased survival and an enriched quality of life for thousands of patients.
  72. [72]
    Domestic & International Donor Centers - NMDP
    Find a NMDP donor center near you. If you're called to donate, our donor center teams will be there to walk you through every step of the donation process.Missing: agreements | Show results with:agreements
  73. [73]
    Network | NMDP
    Clinical trials research through NMDP Donor for All shows that patients can safely receive HCT using cells from a partially matched donor. Just as important, ...Donor assessment · NMDP HLA Today · NMDP CordSource® resources · About Us
  74. [74]
    Credentials - Gift of Life
    NMDP. Gift of Life's Marrow Donor Program meets annual NMDP compliance requirements. Gift of Life and NMDP are contracted as associate donor registries.<|separator|>
  75. [75]
    Act Now: C.W. Bill Young Cell Transplantation Program - NMDP
    In 1979, Laura Graves received the first unrelated bone marrow transplant for leukemia. Her parents wanted other families to have the same hope for a cure, so ...Missing: case | Show results with:case
  76. [76]
    U.S. Transplant Center Directory - NMDP
    We partner with more than 150 transplant centers across the United States to facilitate blood stem cell transplants, support patients and conduct research.Yale University/yale New... · Mass General Brigham Cancer... · Sanford Health
  77. [77]
    NMDP Board of Directors
    The NMDP board of directors provides oversight and guidance to our executive team. Judith Gasson, PhD, Board Chair.Missing: structure | Show results with:structure
  78. [78]
    Executive Team - NMDP
    NMDP's executive team is comprised of leaders with the expertise that enables us to best serve our donors, patients and the entire transplant community.Missing: structure | Show results with:structure
  79. [79]
    [PDF] National Marrow Donor Program and Subsidiaries
    Sep 30, 2024 · The Organization aims to provide a diverse listing of potential donors ... As part of the Organization's liquidity management, the Organization ...
  80. [80]
    [PDF] Now Making Dreams Possible - NMDP
    These videos aim to clearly explain the NMDP BioTherapies donation process and share one donor's story. IN 2024, 45,317 NMDP REGISTRY MEMBERS. OPTED IN TO ...
  81. [81]
    Financial statements - NMDP
    Our annual reports are an opportunity to highlight our successes, demonstrate how we measured up to our goals and thank those who help make it all happen.Financial Reports · Annual Reports · Foundation Irs Form 990Missing: size | Show results with:size
  82. [82]
    https://www.nmdp.org/what-we-do/about-us/leadership/board-of-directors